Degoricija Vesna, Sharma Mirella, Legac Ante, Gradiser Marina, Sefer Sinisa, Vucicević Zeljko
Vesna Degoricija, Department of Medicine, Intensive Care Unit, Sisters of Mercy University Hospital, Vinogradska cesta 29, 10000 Zagreb, Croatia,
Croat Med J. 2006 Jun;47(3):385-97.
To evaluate epidemiology of sepsis in medical intensive care unit (ICU) in a university hospital, and the impact of ICU performance and appropriate empirical antibiotic therapy on survival of septic patients.
Observational, partly prospective study conducted over 6 years assessed all patients meeting the criteria for sepsis at ICU admission at the Sisters of Mercy University Hospital. Clinical presentation of sepsis was defined according to 2001 International Sepsis Definitions Conference. Demographic data, admission category, source of infection, severity of sepsis, ICU or hospital stay and outcome, ICU performance, and appropriateness of empirical antibiotic therapy were analyzed.
The analysis included 314 of 5022 (6.3%) patients admitted to ICU during the study period. There were 176 (56.1%) ICU survivors. At the ICU admission, sepsis was present in 100 (31.8%), severe sepsis in 89 (28.6%), and septic shock in 125 (39.8%) patients with mortality rates 17%, 33.7%, 72.1%, respectively. During ICU treatment, 244 (77.7%) patients developed at least one organ dysfunction syndrome. Of 138 (43.9%) patients who met the criteria for septic shock, 107 (75.4) were non-survivors (P<0.001). Factors associated with in-ICU mortality were acquisition of sepsis at another department (odds ratio [OR] 0.06; 95% confidence interval [CI], 0.02-0.19), winter season (OR 0.42; 0.20-0.89), limited mobility (OR 0.28; 0.14-0.59), ICU length of stay (OR 0.82; 0.75-0.91), sepsis-related organ failure assessment (SOFA) score on day 1 (OR 0.80; 0.72-0.89), history of global heart failure (OR 0.33; 0.16-0.67), chronic obstructive pulmonary disease (COPD)-connected respiratory failure (OR 0.50; 0.27-0.93), septic shock present during ICU treatment (OR 0.03; 0.01-0.10), and negative blood culture at admission (OR 2.60; 0.81-6.23). Microbiological documentation of sepsis was obtained in 235 (74.8%) patients. Urinary tract infections were present in 168 (53.5%) patients, followed by skin or soft tissue infections in 58 (18.5%) and lower respiratory tract infections in 44 (14.0%) patients. Lower respiratory tract as focus of sepsis was connected with worse outcome (P<0.001). Empirical antibiotic treatment was considered adequate in 107 (60.8%) survivors and 42 (30.4%) non-survivors. Patients treated with adequate empirical antibiotic therapy had significantly higher survival time in hospital (log-rank, P=0.001).
The mortality rate of sepsis was unacceptably high. The odds for poor outcome increased with acquisition of sepsis at another department, winter season, limited mobility, higher SOFA score on day 1, history of chronic global heart failure, COPD-connected respiratory failure, and septic shock present during ICU treatment, whereas longer ICU length of stay, positive blood culture, and adequate empirical antibiotic therapy were protective factors.
评估某大学医院医学重症监护病房(ICU)中脓毒症的流行病学情况,以及ICU绩效和适当的经验性抗生素治疗对脓毒症患者生存的影响。
在6年期间进行的观察性、部分前瞻性研究,评估了在仁慈大学医院ICU入院时符合脓毒症标准的所有患者。脓毒症的临床表现根据2001年国际脓毒症定义会议确定。分析了人口统计学数据、入院类别、感染源、脓毒症严重程度、ICU或住院时间及结局、ICU绩效以及经验性抗生素治疗的适当性。
分析纳入了研究期间入住ICU的5022例患者中的314例(6.3%)。有176例(56.1%)患者在ICU存活。在ICU入院时,100例(31.8%)患者存在脓毒症,89例(28.6%)为严重脓毒症,125例(39.8%)为脓毒性休克,死亡率分别为17%、33.7%、72.1%。在ICU治疗期间,244例(77.7%)患者发生了至少一种器官功能障碍综合征。在符合脓毒性休克标准的138例(43.9%)患者中,107例(75.4%)死亡(P<0.001)。与ICU内死亡率相关的因素包括在其他科室发生脓毒症(比值比[OR]0.06;95%置信区间[CI],0.02 - 0.19)、冬季(OR 0.42;0.20 - 0.89)、活动受限(OR 0.28;0.14 - 0.59)、ICU住院时间(OR 0.82;0.75 - 0.91)、第1天的脓毒症相关器官功能衰竭评估(SOFA)评分(OR 0.80;0.72 - 0.89)、全心衰病史(OR 0.33;0.16 - 0.67)、慢性阻塞性肺疾病(COPD)相关呼吸衰竭(OR 0.50;0.27 - 0.93)、ICU治疗期间出现脓毒性休克(OR 0.03;0.01 - 0.10)以及入院时血培养阴性(OR 2.60;0.81 - 6.23)。235例(74.8%)患者获得了脓毒症的微生物学证据。168例(53.5%)患者存在尿路感染;其次是58例(18.5%)皮肤或软组织感染和44例(14.0%)下呼吸道感染。以脓毒症为重点的下呼吸道感染与更差的结局相关(P<0.001)。107例(60.8%)存活患者和42例(30.4%)死亡患者的经验性抗生素治疗被认为是充分的。接受充分经验性抗生素治疗的患者在医院中的生存时间显著更长(对数秩检验,P = 0.001)。
脓毒症的死亡率高得令人无法接受。在其他科室发生脓毒症、冬季、活动受限、第1天SOFA评分较高、慢性全心衰病史、COPD相关呼吸衰竭以及ICU治疗期间出现脓毒性休克会增加不良结局的几率,而更长的ICU住院时间、血培养阳性以及充分的经验性抗生素治疗是保护因素。